DDInter392 DDInter1657
An antineoplastic agent used in the treatment of lymphoproliferative diseases including hairy-cell leukemia.
Selinexor is a first-in-class selective inhibitor of nuclear transport (SINE) compound. Selinexor, in combination with [bortezomib] and [dexamethasone], is currently approved for the treatment of multiple myeloma, a type of cancer formed from antibody-producing plasma cells.[L7117,L7120,L10145] This condition is typically treated with high dose [bortezomib] and [dexamethasone] chemotherapy followed by an autologous stem-cell transplant. Other chemotherapies for multiple myeloma include [lenalidomide] and [dexamethasone], [thalidomide], and may include [melphalan] if the patient is not eligible for transplant. Selinexor was also granted accelerated approval for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) that have gone through at least 2 lines of systemic therapy. The FDA approved Selinexor in June 2019. The use of selinexor in combination with [bortezomib] and [dexamethasone] was approved by Health Canada in June 2022 for the treatment of multiple myeloma in adult patients who have received at least one prior therapy.
Cladribine {u} (Compound) resembles {v} (Compound) Vidarabine
Cladribine {u} (Compound) resembles {v} (Compound) Nelarabine
Cladribine {u} may lead to a major life threatening interaction when taken with {v} Azacitidine
Cladribine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Abacavir
Cladribine {u} (Compound) treats {v} (Disease) hematologic cancer
Cladribine {u} (Compound) binds {v} (Gene) PNP
Cladribine {u} (Compound) upregulates {v} (Gene) RGS2
Cladribine {u} (Compound) downregulates {v} (Gene) PLK1
Cladribine {u} (Compound) causes {v} (Side Effect) Cardiac disorder
Cladribine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Reserpine
Cladribine (Compound) resembles Vidarabine (Compound)
Cladribine (Compound) resembles Nelarabine (Compound)
Cladribine may lead to a major life threatening interaction when taken with Azacitidine
Cladribine may cause a moderate interaction that could exacerbate diseases when taken with Abacavir
Cladribine (Compound) treats hematologic cancer (Disease)
Cladribine (Compound) binds PNP (Gene)
Cladribine (Compound) upregulates RGS2 (Gene)
Cladribine (Compound) downregulates PLK1 (Gene)
Cladribine (Compound) causes Cardiac disorder (Side Effect)
Cladribine may cause a moderate interaction that could exacerbate diseases when taken with Reserpine